Tin T. Win, M.D., Dismissal of Proceeding, 52802-52803 [2013-20676]

Download as PDF 52802 Federal Register / Vol. 78, No. 165 / Monday, August 26, 2013 / Notices Dated: August 20, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2013–20724 Filed 8–23–13; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application; Cambridge Isotope Lab Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on July 01, 2013, Cambridge Isotope Lab, 50 Frontage Road, Andover, Massachusetts 01810, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Morphine (9300), a basic class of controlled substance listed in schedule II. The company plans to utilize small quantities of the listed controlled substance in the preparation of analytical standards. Any other such applicant, and any person who is presently registered with DEA to manufacture such a substance, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR § 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than October 25, 2013. Dated: August 15, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2013–20723 Filed 8–23–13; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration ehiers on DSK2VPTVN1PROD with NOTICES Manufacturer of Controlled Substances; Notice of Registration; Morton Grove Pharmaceuticals By Notice dated March 12, 2013, and published in the Federal Register on March 20, 2013, 78 FR 17231, Morton Grove Pharmaceuticals, 6451 Main Street, Morton Grove, Illinois 60053– 2633, made application by renewal to the Drug Enforcement Administration VerDate Mar<15>2010 13:45 Aug 23, 2013 Jkt 229001 (DEA) to be registered as a bulk manufacturer of Gamma Hydroxybutyric Acid (2010), a basic class of controlled substance listed in schedule I. The company plans to manufacture the listed controlled substance for distribution to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a), and determined that the registration of Morton Grove Pharmaceuticals to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated Morton Grove Pharmaceuticals to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems; verification of the company’s compliance with state and local laws; and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class of controlled substance listed. Dated: August 15, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2013–20761 Filed 8–23–13; 8:45 am] No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Navinta, LLC., to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Navinta, LLC., to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: August 15, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2013–20757 Filed 8–23–13; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Tin T. Win, M.D., Dismissal of Proceeding BILLING CODE 4410–09–P On February 27, 2013, I, the Administrator of the Drug Enforcement Administration, issued an Order to DEPARTMENT OF JUSTICE Show Cause and Immediate Suspension of Registration to Tin T. Win, M.D. Drug Enforcement Administration (hereinafter, Registrant), of Lake Havasu, Arizona. GX 10, at 1. Among various Manufacturer of Controlled charges, the Order alleged that Substances; Notice of Registration: Registrant issued numerous controlled Navinta, LLC substance prescriptions after the By Notice dated April 10, 2013, and Arizona Medical Board had prohibited published in the Federal Register on her ‘‘from prescribing controlled April 19, 2013, 78 FR 23596, Navinta, substances’’ and thus violated both the LLC., 1499 Lower Ferry Road, Ewing, Board’s order and federal law. Id. at 1– New Jersey 08618–1414, made 3 (citing Ariz. Rev. Stat. § 32– application to the Drug Enforcement 1401(27)(r); 21 U.S.C. 841). The Order Administration (DEA) to be registered as also notified Registrant of her right to a bulk manufacturer of the following either request a hearing on the basic classes of controlled substances: allegations or submit a written statement of position in lieu of a hearing Drug Schedule within thirty (30) days of her receipt of Pentobarbital (2270) ..................... II the Order, the procedure for electing Remifentanil (9739) ...................... II either option, and the consequence of failing to elect either option. The company plans initially to On March 6, 2013, the Order was manufacture API quantities of the listed personally served on Registrant by a controlled substances for validation DEA Special Agent and a Diversion purposes and FDA approval, then to Investigator. See GX 11. On May 20, produce commercial size batches for 2013, the Government filed a Request distribution to dosage form for Final Agency Action, which sought manufacturers upon FDA approval. the revocation of Registrant’s PO 00000 Frm 00045 Fmt 4703 Sfmt 4703 E:\FR\FM\26AUN1.SGM 26AUN1 Federal Register / Vol. 78, No. 165 / Monday, August 26, 2013 / Notices registration. Request for Final Agency Action, at 12. Therein, the Government represented that neither Registrant, nor anyone purporting to represent her, had filed either a request for a hearing or a written statement in lieu of a hearing. Id. at 2. Upon review of the record, the Government’s evidence showed that Registrant’s registration was due to expire on May 31, 2013. See GX 2. However, because the filing of a timely renewal application would have prevented the expiration of her registration (albeit in suspended status), see 5 U.S.C. 556(e), I took official notice of her registration record with the Agency. According to that record, Registrant did not file either a renewal application or a new application. The Agency therefore deemed her registration as expired and retired her registration number. While ordinarily these findings render a case moot, see Ronald J. Riegel, 63 FR 67132, 67133 (1998), simultaneously with the issuance of the Order to Show Cause, I immediately suspended Registrant’s registration. Because the Immediate Suspension Order also authorized the Government to seize any controlled substances in Registrant’s possession, and thus created the possibility that a collateral consequence existed which precludes a finding of mootness, see Robert Charles Ley, 76 FR 20033, 20034 (2011), I directed the Government to notify my Office as to whether it had seized any controlled substances. Order (July 15, 2013). On July 22, 2013, the Government notified my Office that it had not seized any controlled substances pursuant to the Immediate Suspension Order. Gov. Response Regarding Mootness, at 2. The Government further acknowledged that this ‘‘case is now moot.’’ Id. Accordingly, I will dismiss this proceeding. See Ley, 76 FR at 20034. ehiers on DSK2VPTVN1PROD with NOTICES Order Pursuant to the authority vested in me by 21 U.S.C. 824(a), as well as 28 CFR 0.100(b), I order that the Order to Show Cause and Immediate Suspension of Registration issued to Tin T. Win, M.D., be, and it hereby is, dismissed. This Order is effective immediately. Dated: August 16, 2013. Michele M. Leonhart, Administrator. BILLING CODE 4410–09–P 13:45 Aug 23, 2013 Office of the Secretary Agency Information Collection Activities; Submission for OMB Review; Comment Request; Additional Information Collection Requirements for Special Dipping and Coating Operations ACTION: Notice. The Department of Labor (DOL) is submitting the Occupational Safety and Health Administration (OSHA) sponsored information collection request (ICR) titled, ‘‘Additional Information Collection Requirements for Special Dipping and Coating Operations,’’ to the Office of Management and Budget (OMB) for review and approval for continued use, without change, in accordance with the Paperwork Reduction Act (PRA) of 1995 (44 U.S.C. 3501 et seq.). DATES: Submit comments on or before September 25, 2013. ADDRESSES: A copy of this ICR with applicable supporting documentation; including a description of the likely respondents, proposed frequency of response, and estimated total burden may be obtained free of charge from the RegInfo.gov Web site at http:// www.reginfo.gov/public/do/PRA ViewICR?ref_nbr=201306–1218–003 (this link will only become active on the day following publication of this notice) or by contacting Michel Smyth by telephone at 202–693–4129 (this is not a toll-free number) or sending an email to DOL_PRA_PUBLIC@dol.gov. Submit comments about this request to the Office of Information and Regulatory Affairs, Attn: OMB Desk Officer for DOL–OSHA, Office of Management and Budget, Room 10235, 725 17th Street NW., Washington, DC 20503, Fax: 202–395–6881 (this is not a toll-free number), email: OIRA_ submission@omb.eop.gov. Commenters are encouraged, but not required, to send a courtesy copy of any comments to the U.S. Department of LaborOASAM, Office of the Chief Information Officer, Attn: Information Management Program, Room N1301, 200 Constitution Avenue NW., Washington, DC 20210, email: DOL_PRA_PUBLIC@dol.gov. FOR FURTHER INFORMATION CONTACT: Michel Smyth by telephone at 202–693– 4129 (this is not a toll-free number) or by email at DOL_PRA_PUBLIC@dol.gov. SUMMARY: Authority: 44 U.S.C. 3507(a)(1)(D). [FR Doc. 2013–20676 Filed 8–23–13; 8:45 am] VerDate Mar<15>2010 DEPARTMENT OF LABOR Jkt 229001 The Dipping and Coating Operations Standard requires employers to post a SUPPLEMENTARY INFORMATION: PO 00000 Frm 00046 Fmt 4703 Sfmt 4703 52803 conspicuous sign near each piece of electrostatic detearing equipment that notifies employees of the minimum safe distance they must maintain between goods undergoing electrostatic detearing and the electrodes or conductors of the equipment used in the process. See 29 CFR 1910.126(g)(4). This information collection is subject to the PRA. A Federal agency generally cannot conduct or sponsor a collection of information, and the public is generally not required to respond to an information collection, unless it is approved by the OMB under the PRA and displays a currently valid OMB Control Number. In addition, notwithstanding any other provisions of law, no person shall generally be subject to penalty for failing to comply with a collection of information that does not display a valid Control Number. See 5 CFR 1320.5(a) and 1320.6. The DOL obtains OMB approval for this information collection under Control Number 1218–0237. For additional substantive information about this ICR, see the related notice published in the Federal Register on April 9, 2013 (78 FR 21159). OMB authorization for an ICR cannot be for more than three (3) years without renewal, and the current approval for this collection is scheduled to expire on December 31, 2013. The DOL seeks to extend PRA authorization for this information collection for three (3) more years, without any change to existing requirements. It should also be noted that existing information collection requirements submitted to the OMB receive a month-to-month extension while they undergo review. Interested parties are encouraged to send comments to the OMB, Office of Information and Regulatory Affairs at the address shown in the ADDRESSES section within 30 days of publication of this notice in the Federal Register. In order to help ensure appropriate consideration, comments should mention OMB Control Number 1218– 0237. The OMB is particularly interested in comments that: • Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; • Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; • Enhance the quality, utility, and clarity of the information to be collected; and E:\FR\FM\26AUN1.SGM 26AUN1

Agencies

[Federal Register Volume 78, Number 165 (Monday, August 26, 2013)]
[Notices]
[Pages 52802-52803]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-20676]


-----------------------------------------------------------------------

 DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Tin T. Win, M.D., Dismissal of Proceeding

    On February 27, 2013, I, the Administrator of the Drug Enforcement 
Administration, issued an Order to Show Cause and Immediate Suspension 
of Registration to Tin T. Win, M.D. (hereinafter, Registrant), of Lake 
Havasu, Arizona. GX 10, at 1. Among various charges, the Order alleged 
that Registrant issued numerous controlled substance prescriptions 
after the Arizona Medical Board had prohibited her ``from prescribing 
controlled substances'' and thus violated both the Board's order and 
federal law. Id. at 1-3 (citing Ariz. Rev. Stat. Sec.  32-1401(27)(r); 
21 U.S.C. 841). The Order also notified Registrant of her right to 
either request a hearing on the allegations or submit a written 
statement of position in lieu of a hearing within thirty (30) days of 
her receipt of the Order, the procedure for electing either option, and 
the consequence of failing to elect either option.
    On March 6, 2013, the Order was personally served on Registrant by 
a DEA Special Agent and a Diversion Investigator. See GX 11. On May 20, 
2013, the Government filed a Request for Final Agency Action, which 
sought the revocation of Registrant's

[[Page 52803]]

registration. Request for Final Agency Action, at 12. Therein, the 
Government represented that neither Registrant, nor anyone purporting 
to represent her, had filed either a request for a hearing or a written 
statement in lieu of a hearing. Id. at 2.
    Upon review of the record, the Government's evidence showed that 
Registrant's registration was due to expire on May 31, 2013. See GX 2. 
However, because the filing of a timely renewal application would have 
prevented the expiration of her registration (albeit in suspended 
status), see 5 U.S.C. 556(e), I took official notice of her 
registration record with the Agency. According to that record, 
Registrant did not file either a renewal application or a new 
application. The Agency therefore deemed her registration as expired 
and retired her registration number.
    While ordinarily these findings render a case moot, see Ronald J. 
Riegel, 63 FR 67132, 67133 (1998), simultaneously with the issuance of 
the Order to Show Cause, I immediately suspended Registrant's 
registration. Because the Immediate Suspension Order also authorized 
the Government to seize any controlled substances in Registrant's 
possession, and thus created the possibility that a collateral 
consequence existed which precludes a finding of mootness, see Robert 
Charles Ley, 76 FR 20033, 20034 (2011), I directed the Government to 
notify my Office as to whether it had seized any controlled substances. 
Order (July 15, 2013).
    On July 22, 2013, the Government notified my Office that it had not 
seized any controlled substances pursuant to the Immediate Suspension 
Order. Gov. Response Regarding Mootness, at 2. The Government further 
acknowledged that this ``case is now moot.'' Id. Accordingly, I will 
dismiss this proceeding. See Ley, 76 FR at 20034.

Order

    Pursuant to the authority vested in me by 21 U.S.C. 824(a), as well 
as 28 CFR 0.100(b), I order that the Order to Show Cause and Immediate 
Suspension of Registration issued to Tin T. Win, M.D., be, and it 
hereby is, dismissed. This Order is effective immediately.

    Dated: August 16, 2013.
Michele M. Leonhart,
Administrator.
[FR Doc. 2013-20676 Filed 8-23-13; 8:45 am]
BILLING CODE 4410-09-P